Proteasome Inhibitors in Cancer Therapy Image close
Proteasome Inhibitors in Cancer Therapy on Hardback
Proteasome Inhibitors in Cancer Therapy on Hardback
Show Hide Adult Content
Proteasome Inhibitors in Cancer Therapy close

Non-Fiction Books:

Home  
Books  
Non-Fiction  
Professional & Technical  
Medicine  
Clinical & internal medicine  
Diseases & disorders  
Oncology

Proteasome Inhibitors in Cancer Therapy

Click to share your rating 0 ratings (0.0/5.0 average) Thanks for your vote!

Format:

Hardback
$407.99
RRP:
$521.95 save $113.96
Available from supplier

The item is brand new and in-stock with one of our preferred suppliers. The item will ship from a Mighty Ape warehouse within the timeframe shown.

Usually ships in 3-4 weeks
0 in Trolley

Buy Now, Pay Later with:

4 payments of $102.00 with Afterpay Learn more

Availability

Delivering to:

Estimated arrival:

  • Around 25 Jun - 5 Jul using International Courier

Explore more Cancer Drug Discovery and Development

See all products in this series

Farnesyltransferase Inhibitors in Cancer Therapy on Hardback Save $50
$404.99
$455.95
Farnesyltransferase Inhibitors in Cancer Therapy
Hardback
Available - Usually ships in 3-4 weeks
Checkpoint Controls and Targets in Cancer Therapy Save $13
$401.99
$415.95
Checkpoint Controls and Targets in Cancer Therapy
Paperback / softback
Available - Usually ships in 3-4 weeks
Hypoxia and Cancer on Hardback Save $10
$404.99
$415.95
Hypoxia and Cancer
Hardback
Available - Usually ships in 3-4 weeks
Macromolecular Anticancer Therapeutics on Hardback
$713.99
Macromolecular Anticancer Therapeutics
Hardback
Available - Usually ships in 3-4 weeks
Apoptosis and Cancer Chemotherapy Save $168
$286.99
$455.95
Apoptosis and Cancer Chemotherapy
Paperback / softback
Available - Usually ships in 3-4 weeks
Gene Therapy for Cancer on Hardback Save $36
$529.99
$566.95
Gene Therapy for Cancer
Hardback
Available - Usually ships in 3-4 weeks
DNA Topoisomerases and Cancer
$519.99
DNA Topoisomerases and Cancer
Paperback / softback
Available - Usually ships in 3-4 weeks
Nitric Oxide (NO) and Cancer on Hardback Save $153
$526.99
$680.95
Nitric Oxide (NO) and Cancer
Hardback
Available - Usually ships in 3-4 weeks
DNA Topoisomerases and Cancer on Hardback
$521.99
DNA Topoisomerases and Cancer
Hardback
Available - Usually ships in 3-4 weeks
Advances in DNA Repair in Cancer Therapy on Hardback
$518.99
Advances in DNA Repair in Cancer Therapy
Hardback
Available - Usually ships in 3-4 weeks
Sensitization of Cancer Cells for Chemo/Immuno/Radio-therapy
$542.99
Sensitization of Cancer Cells for Chemo/Immuno/Radio-therapy
Paperback / softback
Available - Usually ships in 3-4 weeks
COX-2 Blockade in Cancer Prevention and Therapy on Hardback Save $111
$409.99
$521.95
COX-2 Blockade in Cancer Prevention and Therapy
Hardback
Available - Usually ships in 3-4 weeks
PARP Inhibitors for Cancer Therapy on Hardback
$400.99
PARP Inhibitors for Cancer Therapy
Hardback
Available - Usually ships in 3-4 weeks
Checkpoint Controls and Targets in Cancer Therapy on Hardback Save $49
$406.99
$456.95
Checkpoint Controls and Targets in Cancer Therapy
Hardback
Available - Usually ships in 3-4 weeks
Innovations for Next-Generation Antibody-Drug Conjugates
$399.99
Innovations for Next-Generation Antibody-Drug Conjugates
Paperback / softback
Available - Usually ships in 3-4 weeks
Ex Vivo Engineering of the Tumor Microenvironment on Hardback
$397.99
Ex Vivo Engineering of the Tumor Microenvironment
Hardback
Available - Usually ships in 3-4 weeks

Description

A panel of leading academic and pharmaceutical investigators takes stock of the remarkable work that has been accomplished to date with proteasome inhibitors in cancer, and examines emerging therapeutic possibilities. The topics range from a discussion of the chemistry and cell biology of the proteasome and the rationale for proteasome inhibitors in cancer to a review of current clinical trials underway. The discussion of rationales for testing proteasome inhibitors in cancer models covers the role of the proteasome in NF-kB activation, the combining of conventional chemotherapy and radiation with proteasome inhibition, notably PS-341, new proteasome methods of inhibiting viral maturation, and the role of protesome inhibition in the treatment of AIDS. The authors also document the development of bortezomib (Velcade ) in Phase I clinical trials and in a multicentered Phase II clinical trials in patients with relapsed and refractory myeloma.
Release date Australia
May 25th, 2004
Audiences
  • Postgraduate, Research & Scholarly
  • Professional & Vocational
  • Undergraduate
Contributor
  • Edited by Julian Adams
Illustrations
XV, 313 p.
Pages
313
Dimensions
178x254x24
ISBN-13
9781588292506
Product ID
5804636

Customer reviews

Nobody has reviewed this product yet. You could be the first!

Write a Review

Marketplace listings

There are no Marketplace listings available for this product currently.
Already own it? Create a free listing and pay just 9% commission when it sells!

Sell Yours Here

Recommended for you

Recommended from your browsing history

Help & options

Filed under...

Books >
Non-Fiction >
Professional & Technical >
Medicine >
Clinical & internal medicine >
Diseases & disorders >
Oncology